← Eichor
Study identifier: NCT06826612 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

Condition: Huntington Disease  ·  Sponsor: Hoffmann-La Roche

PhasePhase 1/Phase 2
Planned participants53
Who can joinAll sexes, 25 Years to 65 Years
Healthy volunteersNo

About this study

The main goal of this study is to evaluate the safety, tolerability, and preliminary efficacy of SPK-10001 in participants with Huntington's Disease.

This description comes directly from the study's public registry record.

Talk to the study team

Reference Study ID Number: SPK-10001-101 https://forpatients.roche.com/  ·  888-662-6728  ·  global-roche-genentech-trials@gene.com

Always discuss trial participation with your own doctor first.

Locations (5)

Beth Israel Deaconess Medical CenterBoston, Massachusetts, United StatesRecruiting
University of Cincinnati/Cincinnati Children's HospitalCincinnati, Ohio, United StatesRecruiting
Ohio State UniversityColumbus, Ohio, United StatesRecruiting
University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesRecruiting
University of PittsburgPittsburgh, Pennsylvania, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06826612